RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Pharmacological Articles

FDA will complete its review of REMOXY ER in August 2018.
In his new book, Medication Management of Chronic Pain: What You Need to Know, Gerald M. Aronoff, MD, DABPM, DABPN, medical director of Carolina Pain Associates in Charlotte, North Carolina, and former president of the American Academy of Pain Medicine, presents data to assist practitioners in their decision-making regarding medication management of complex chronic pain problems.
This article provides a sneak preview into the upcoming July/August 2018 issue of Practical Pain Management.
The agency said it will continue to evaluate the use of market drugs and take regulatory action where needed.
With opioid misuse and abuse on the rise, other opioid receptors may be targeted for pain relief.
Knowing a patient has consumed their prescribed medication may prevent improper diversion of pills and overdose.
If approved by FDA, IV tramadol would be the first Schedule IV intravenous opioid in the US.
AcelRx is planning on resubmitting an NDA for DSUVIA to FDA in Q2 2018.
Elevated use of gabapentinoid misuse and abuse may be a problem with monitoring opioids.
Small doses could help children suffering from various types of inflammation and pain.
For the rare complex regional pain syndrome, help may be on the way in the form of this cannabidiol.
With appropriate treatment and follow-up, individuals can reach sustained long-term remission from OUD.
Nonopioid Management Just as Impactful as Opioids for Knee/OA Pain
New lead into understanding the pathophysiology of opioid physical dependence
Chronic neuropathy treatment does not offer much pain relief for patients.
SHOW MAIN MENU
SHOW SUB MENU